自2019年12月武漢首次出現(xiàn)新型冠狀病毒肺炎（COVID-19），越來越多人被確診，已經(jīng)擴(kuò)散到了中國各地和境外多個(gè)國家。由于尚沒有特效藥，很多已被批準(zhǔn)的"老藥"被用于COVID-19的臨床治療中。青蒿素是世界衛(wèi)生組織推薦的一線抗瘧藥物，研究發(fā)現(xiàn)其還具有抗炎、免疫調(diào)節(jié)、抗肺纖維化、抗菌、抗病毒、心血管作用等多種藥理作用。綜述了青蒿素及其衍生物抗COVID-19相關(guān)的藥理作用及其作用機(jī)制，以挖掘其潛在的藥用價(jià)值，重點(diǎn)探討了其用于治療COVID-19的可行性，為發(fā)掘有效的治療藥物提供參考。

Since the initial cases of the Coronavirus Disease in 2019 (COVID-19) occurred in Wuhan in December 2019, more and more cases have been found and confirmed, not only in central China but also in other countries. Given there are still no effective drugs many approved "old drugs" are in clinical test for treating COVID-19 at present. Artemisinin, a first-line antimalarial drug recommended by WHO, has been validated to possess a variety of pharmacological effects, including, without limitation, antiinflammatory, immune regulation, anti-pulmonary fibrosis, antibacterial, antiviral and cardiovascular effects, and the like. In this paper, various pharmacological effects of Artemisinin and its derivatives have been summarized, with the emphasis on the mechanism of action, so as to explore its potential medicinal value, especially for treating COVID-19.

R285.6

國家科技重大專項(xiàng)"中醫(yī)藥優(yōu)勢領(lǐng)域的創(chuàng)新中藥關(guān)鍵技術(shù)開發(fā)研究"（2017ZX09301005）；山東省重點(diǎn)研發(fā)計(jì)劃"新型冠狀病毒潛在藥物臨床評價(jià)研究"（2020SFXGFY07）